Latigo Biotherapeutics, Inc.

Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights

Phase 3 bunionectomy and open-label safety trials of onzotrigine remain on track for initiation with topline results expected in the second half of…